Endometrial Cancer: Chemo-Radiation Boosts Long-Term Survival

A decade of data from the pivotal PORTEC-3 trial confirms a significant, though nuanced, benefit to adding chemotherapy to radiation therapy for high-risk endometrial cancer. While the initial results showed promise, these 10-year follow-up findings, published in The Lancet Oncology, solidify chemoradiotherapy as a valuable treatment option – but crucially, not for all patients. This isn’t simply about extending survival; it’s about identifying *who* benefits most, paving the way for a more personalized approach to endometrial cancer treatment.

Endometrial cancer, the most common gynecologic malignancy in the United States, is seeing increasing incidence rates. While early-stage disease is often curable with surgery and radiation, high-risk cases – those with deep myometrial invasion, lymph node involvement, or aggressive histology – require adjuvant therapy to prevent recurrence. For years, the question has been whether adding chemotherapy to radiation improves outcomes. The PORTEC-3 trial, initiated in 2006, aimed to answer that question, and this latest analysis provides the longest follow-up to date.

The trial randomly assigned 660 patients to either chemoradiotherapy (cisplatin followed by carboplatin and paclitaxel) or radiotherapy alone. The 10-year overall survival rate was 74.4% with chemoradiotherapy versus 67.3% with radiotherapy alone – a statistically significant improvement. Recurrence-free survival also favored the chemoradiotherapy arm. However, the real story lies in the subgroup analysis. Patients with p53 abnormal tumors experienced a dramatic survival benefit with the addition of chemotherapy, while those with POLE mutations or dMMR disease did not.

This molecular stratification is a game-changer. Previously, adjuvant treatment decisions were largely based on clinical factors like stage and grade. Now, molecular testing – assessing p53 status, POLE mutation status, and mismatch repair deficiency – is poised to become standard practice. This allows clinicians to tailor treatment to the individual patient’s tumor biology, avoiding unnecessary chemotherapy and its associated toxicities in those who won’t benefit.

What Happens Next?

The implications of PORTEC-3 extend beyond immediate clinical practice. We can anticipate several key developments:

• Increased Molecular Testing: Expect a rapid increase in the adoption of molecular testing for endometrial cancer, driven by insurance coverage and guideline updates.
• Refinement of Guidelines: National Comprehensive Cancer Network (NCCN) and other guidelines will likely be updated to incorporate molecular stratification into adjuvant treatment recommendations.
• Further Research: This data will fuel further research into the mechanisms underlying the differential response to chemotherapy based on molecular subtype. Investigating novel therapies specifically targeting p53 abnormal tumors is a logical next step.
• Cost-Effectiveness Analyses: Health economic evaluations will be crucial to determine the cost-effectiveness of molecular testing and personalized treatment strategies.

The PORTEC-3 trial’s 10-year data isn’t just a confirmation of existing knowledge; it’s a catalyst for a more precise, personalized approach to treating high-risk endometrial cancer. The future of care will be defined by understanding the unique molecular fingerprint of each tumor and tailoring treatment accordingly, maximizing benefit while minimizing harm.

Reference

Post CCB, de Boer SM, Powell ME, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. Lancet Oncol. 2025;26(10):1370-1381. doi:10.1016/S1470-2045(25)00379-1